F.D.A. Approves Prostate Cancer Drug
Xtandi, which was developed by Medivation and Astellas Pharma, was shown to extend the life of men with late-stage cancer by nearly five months.
Xtandi, which was developed by Medivation and Astellas Pharma, was shown to extend the life of men with late-stage cancer by nearly five months.